A randomized clinical trial to evaluate the efficacy of catecholamine surge supression by oral azilsartan in patients with hypertensive intracerebral hemorrhage

Trial Profile

A randomized clinical trial to evaluate the efficacy of catecholamine surge supression by oral azilsartan in patients with hypertensive intracerebral hemorrhage

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2016

At a glance

  • Drugs Azilsartan (Primary) ; Candesartan cilexetil
  • Indications Cerebral haemorrhage; Hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 20 Jun 2016 Planned End Date changed from 30 Jun 2015 to 30 Jun 2016.
    • 20 Jan 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top